On Thursday, Shares of Alcoa Inc. (NYSE:AA), lost -0.30% to $9.96, hitting its lowest level.
Alcoa, declared a realignment of its downstream segment as the Company’s value-add portfolio expands. Alcoa’s downstream portfolio will become two segments, one with a core focus on aerospace, and the other centered on the construction and commercial wheels markets. The realignment supports Alcoa’s transformation strategy to build its value-add portfolio for greater profitability.
With Alcoa’s successful acquisition of RTI International Metals, Inc. (NYSE: RTI) recently, the recent acquisitions of Firth Rixson and TITAL, and other innovation-led organic growth investments, the Company continues to deepen its reach into the high-growth aerospace market. The Engineered Products and Solutions (EPS) segment, led by Group President Olivier Jarrault, has been streamlined to enable a core focus on Alcoa’s position as a premier aerospace partner. The EPS group will comprise business units that primarily cater to the aerospace market:
- Alcoa Titanium & Engineered Products, the designation for the newly attained RTI business
- Alcoa Fastening Systems & Rings, and Alcoa Forgings & Extrusions, into which the Firth Rixson business has been integrated, and
- Alcoa Power & Propulsion, which now comprises the TITAL business
Alcoa Inc. produces and manages primary aluminum, fabricated aluminum, and alumina worldwide. The company operates through four segments: Alumina, Primary Metals, Global Rolled Products, and Engineered Products and Solutions.
Shares of Linear Technology Corporation (NASDAQ:LLTC), inclined 1.41% to $40.98, during its last trading session.
Linear Technology Corporation, co-founders Bob Swanson and Bob Dobkin were presented with UBM Canon’s EDN and EE Times ACE Lifetime Achievement Award at a ceremony this week during the Embedded Systems Conference in Santa Clara, California.
Bob Swanson and Bob Dobkin founded Linear Technology in September 1981. Bob Swanson, Executive Chairman of Linear Technology, formerly served as CEO and President, and has been a director of the company since its founding. Bob Dobkin is Chief Technical Officer of Linear Technology. He holds over 100 patents pertaining to Linear integrated circuits, has authored over 50 articles and papers, and is co-editor of the Analog Circuit Design book series published by Elsevier.
Linear Technology Corporation, together with its auxiliaries, designs, manufactures, and markets a line of analog integrated circuits (ICs) worldwide. It produces power administration, data conversion, signal conditioning, radio frequency (RF), and interface ICs; µModule subsystems; and wireless sensor network products.
Finally, CytRx Corporation (NASDAQ:CYTR), ended its last trade with -1.06% loss, and closed at $2.80.
Aeterna Zentaris, CytRx Corporation, Synthetic Biologics Inc. (SYN) are three tickers that have recently attracted attention in the Biotech space.
Biotech has mimicked the dot com boom of the early 2000’s quite closely. Several biotech indices and ETFs have shown remarkable growth and have certainly outplaced the overall market. However, growth of this proportion leads to instabilities and overvaluation of many companies. This is exemplified in each of the three companies in focus. AEZS is trading near a 52 – week low after the company received disappointing results from the FDA. Similarly, CtyRx recently declared an offering in which administration offered shares at a noteworthy discount to the market price which resulted in the declines in the stock price. The biotech sector is full of speculation and blind money has been attracted solely by the returns published by both ETFs and Indices that follow this sector. The growth rates will decline and the boom will fall back in line with the market, but some will standout and continue to achieve growth of tremendous proportions.
To pick out the winners, a strict set of characteristics need to be in place. These comprise strong administration backing, a diverse pipeline of drugs entering various stages of development, strength in the balance sheet and liquidity. Those that possess these characteristics can and will follow their own trajectory and will leave the high growing and unstable Biotech market behind.
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
